Overview
- Doctors in Erlangen reported in Med on Thursday that a 47-year-old with autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome entered year-long, treatment-free remission after one CD19 CAR-T dose.
- The patient’s need for daily transfusions ended seven days after infusion, and by day 25 her hemoglobin and other markers of red blood cell destruction had returned to normal.
- The engineered T cells cleared CD19-positive B cells, and when B cells reappeared at day 322 they were mostly naive, indicating an immune reset that removed harmful antibody memory.
- No severe cytokine release syndrome or neurotoxicity was observed, and the therapy used was Miltenyi’s zorpocabtagene autoleucel given under compassionate use.
- Early signals beyond this report include a pediatric case series presented at PRSYM and the CASTLE basket trial in early 2026 that showed strong responses with mild short-term toxicity, while recent reviews outline broader CAR platforms and stress the need for larger trials, long-term safety tracking, and scalable access.